Treats myasthenia gravis. ANDA 211694, held by Novitium Pharma. Pyridostigmine Bromide.
As of Nov 16, 2026, ANDA 211694 (Pyridostigmine Bromide), held by Novitium Pharma, was first approved by FDA on Mar 8, 2019, with 0 approved supplements and 0 published complete response letters.
INDICATION: Pyridostigmine Bromide Oral Solution, USP is useful in the treatment of myasthenia gravis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 8, 2019 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Pyridostigmine Bromide60MG/5ML · syrup;oral | Pyridostigmine Bromide | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters